Results 191 to 200 of about 5,906 (249)
RMD Open, 2021 Objectives To report the impact of burosumab on patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia (XLH) through 96 weeks.
Karine Briot +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Tenofovir-induced osteomalacia with hypophosphataemia
BMJ Case Reports, 2021Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug widely used as a first-line treatment of hepatitis B virus (HBV) and HIV. Increasing evidence has emerged associating its use with the development of Fanconi syndrome, renal insufficiency and bone disease.
Iulia Iatan +2 more
openaire +2 more sources
British Journal of Haematology, 2023
Ferric carboxymaltose (FCM) administration helps reduce transfusion requirements in the perioperative situation, which improves patient outcomes and reduces healthcare costs. However, there is increasing evidence of hypophosphataemia after FCM use.
Zachary Chu +10 more
semanticscholar +1 more source
Ferric carboxymaltose (FCM) administration helps reduce transfusion requirements in the perioperative situation, which improves patient outcomes and reduces healthcare costs. However, there is increasing evidence of hypophosphataemia after FCM use.
Zachary Chu +10 more
semanticscholar +1 more source
Journal of Paediatrics and Child Health, 2023
Hypophosphataemia has been linked to higher morbidity and mortality in intensive care but there is inconsistency in the definition of hypophosphataemia for infants and children.
Bridget S Little +4 more
semanticscholar +1 more source
Hypophosphataemia has been linked to higher morbidity and mortality in intensive care but there is inconsistency in the definition of hypophosphataemia for infants and children.
Bridget S Little +4 more
semanticscholar +1 more source
BMJ Case Reports
Hypocalcaemia and hypophosphataemia are recognised complications of concurrent denosumab and parenteral iron therapy, typically occurring within weeks of administration.
P. Kadappu, Mawson Wang, C. Cho
semanticscholar +1 more source
Hypocalcaemia and hypophosphataemia are recognised complications of concurrent denosumab and parenteral iron therapy, typically occurring within weeks of administration.
P. Kadappu, Mawson Wang, C. Cho
semanticscholar +1 more source
Gut, 2023
We read with interest the paper by Zoller et al comparing the rate of hypophosphataemia with ferric carboxymaltose (FCM) versus ferric derisomaltose (FDI) infusions in patients with inflammatory bowel disease (IBD).
Ayushi Chauhan, S. Lucas, M. Garg
semanticscholar +1 more source
We read with interest the paper by Zoller et al comparing the rate of hypophosphataemia with ferric carboxymaltose (FCM) versus ferric derisomaltose (FDI) infusions in patients with inflammatory bowel disease (IBD).
Ayushi Chauhan, S. Lucas, M. Garg
semanticscholar +1 more source
BMJ Case Reports
Denosumab, an anti-RANKL antibody, induces bone metabolism to a low-turnover bone status by arresting osteoclast activity. Frequent adverse events include infusion reactions, fever and hypocalcaemia but not hypophosphataemia.
Makiko Omori +3 more
semanticscholar +1 more source
Denosumab, an anti-RANKL antibody, induces bone metabolism to a low-turnover bone status by arresting osteoclast activity. Frequent adverse events include infusion reactions, fever and hypocalcaemia but not hypophosphataemia.
Makiko Omori +3 more
semanticscholar +1 more source
Approach to patients with hypophosphataemia
The Lancet Diabetes & Endocrinology, 2020Phosphate metabolism is an evolving area of basic and clinical research. In the past 15 years, knowledge on disturbances of phosphate homoeostasis has expanded, as has the discovery of new targeted therapies. Hypophosphataemia might be the biochemical finding in several diseases, and its clinical evaluation should initially focus on the assessment of ...
Florenzano P. +6 more
openaire +3 more sources
Journal of Crohn's & Colitis
Iron deficiency is common in patients with inflammatory bowel disease (IBD), where poor absorption or prior surgery often renders oral iron supplementation ineffective, necessitating intravenous (IV) iron therapy.
T. Odah, F. Farraye
semanticscholar +1 more source
Iron deficiency is common in patients with inflammatory bowel disease (IBD), where poor absorption or prior surgery often renders oral iron supplementation ineffective, necessitating intravenous (IV) iron therapy.
T. Odah, F. Farraye
semanticscholar +1 more source